钴胺素摄入及相关生物标志物:NHANES中2型糖尿病成人死亡风险的关联研究
该研究纳入NHANES中3277例2型糖尿病成人,随访至2015年12月31日,中位随访7.02年,采用加权Cox回归分析钴胺素摄入及生物标志物与死亡风险的关联。结果显示,血清钴胺素及膳食或补充剂摄入与全因死亡率无稳健关联(各P≥0.120),而甲基丙二酸(MMA)翻倍与全因死亡(HR 1.31)和心脏死亡(HR 1.38)风险升高显著相关;钴胺素敏感性降低(MMA高B12高)组死亡风险最高(HR 1.96),尤其在未使用二甲双胍者中显著。
要点
- 血清及膳食钴胺素与全因死亡率无稳健关联(各P≥0.120)。
- MMA翻倍与全因死亡(HR 1.31)和心脏死亡(HR 1.38)风险升高显著相关。
- MMA高B12高组全因死亡风险最高(HR 1.96),尤其在未使用二甲双胍者中显著。
核心结论
- 血清和膳食钴胺素与死亡率降低无关。
- 钴胺素敏感性降低与全因和心脏死亡率显著相关,尤其在未使用二甲双胍者中。
研究设计与样本
- 研究纳入NHANES中3277例2型糖尿病成人,随访至2015年12月31日。
- 采用加权Cox比例风险回归估计死亡风险的风险比(HR)和95%CI。
主要发现
- 中位随访7.02年期间,3277名参与者中发生865例全因死亡。
- 无论是否接受二甲双胍治疗,全因死亡率与血清钴胺素或食物/补充剂摄入无稳健关联(各P≥0.120)。
- 甲基丙二酸(MMA)翻倍与较高的全因死亡(HR 1.31 [95%CI 1.18-1.45],P<0.001)和心脏死亡(HR 1.38 [95%CI 1.14-1.67],P=0.001)风险显著相关。
- MMAlowB12low、MMAlowB12high、MMAhighB12low和MMAhighB12high组全因死亡的多变量校正HR(95%CI)分别为1.00(参照)、0.98(0.75-1.28)、1.49(1.16-1.92)和1.96(1.38-2.78)。
- 该关联在未使用二甲双胍者中尤其显著。
关键数值与推荐
- 钴胺素敏感性通过B12低/高和MMA低/高的二分类组合评估(切点值:钴胺素400 pg/mL,MMA 250 nmol/L)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite that periodical monitoring of cobalamin (vitamin B12) in metformin-treated patients with diabetes is recommended, cobalamin-associated mortality benefits or risks remain unclear. We investigated the association between cobalamin intake and related biomarkers and mortality risk in adults with diabetes using metformin or not. RESEARCH DESIGN AND METHODS: This study included 3,277 adults with type 2 diabetes from the National Health and Nutrition Examination Survey (NHANES) and followed up until 31 December 2015. Weighted Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs for mortality risk. RESULTS: Among 3,277 participants, 865 all-cause deaths occurred during a median follow-up of 7.02 years. There was no robust relationship between all-cause mortality and serum cobalamin or intake of foods or cobalamin supplements, regardless of metformin treatment (each P ≥ 0.120). The doubling of methylmalonic acid (MMA), a cobalamin-deficiency marker, was significantly associated with higher all-cause (HR 1.31 [95% CI 1.18-1.45], P < 0.001) and cardiac (HR 1.38 [95% CI 1.14-1.67], P = 0.001) mortality. Cobalamin sensitivity was assessed by the combination of binary B12low/high and MMAlow/high (cutoff values: cobalamin 400 pg/mL, MMA 250 nmol/L). Patients with decreased cobalamin sensitivity (MMAhighB12high) had the highest mortality risk. The multivariable-adjusted HRs (95% CIs) of all-cause mortality in MMAlowB12low, MMAlowB12high, MMAhighB12low, and MMAhighB12high groups were 1.00 (reference), 0.98 (0.75-1.28), 1.49 (1.16-1.92), and 1.96 (1.38-2.78), respectively. That association was especially significant in metformin nonusers. CONCLUSIONS: Serum and dietary cobalamin were not associated with reduced mortality. Decreased cobalamin sensitivity was significantly associated with all-cause and cardiac mortality, particularly among metformin nonusers.
引用
- Wang S, Wang Y, Wan X, et al. Cobalamin Intake and Related Biomarkers: Examining Associations With Mortality Risk Among Adults With Type 2 Diabetes in NHANES. Diabetes Care. 2022. PMID: 34862259. doi:10.2337/dc21-1674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。